• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

56.93 +0.08 (+0.14%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,743,035
Open 57.21
Bid (Size) 52.93 (100)
Ask (Size) 58.00 (1,000)
Prev. Close 56.85
Today's Range 56.34 - 57.53
52wk Range 22.59 - 68.73
Shares Outstanding 60,717,176
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026
October 02, 2026
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis
September 23, 2026
From Travere Therapeutics, Inc.
Via Business Wire

Performance

52-Week Range 17.2% below 52-week high
56.93
22.5952W Low 68.7352W High
1 Week 8.0% below 1-week high
56.231W Low 61.871W High

Travere Therapeutics, Inc. - Common Stock (TVTX) traded between $22.59 and $68.73 over the past 52 weeks and last traded at $56.93, 17.2% below its 52-week high. Over the past week it ranged between $56.23 and $61.87.

Past 12 Months
-7.5%
-15.3%
-1.0%
+78.9%
+44.1%
+135.1%
1W -$4.64
1M -$10.30
3M -$0.55
6M +$25.10
YTD +$17.41
1Y +$32.71

TVTX was +135.1% over the past year, +78.9% over six months, +44.1% year to date, -7.5% in the last week.

12 Months vs Market
TVTX
+135.1%
DIA
+9.9%
SPY
+15.0%
QQQ
+23.7%
IWM
+15.4%

Over the past 12 months TVTX returned +135.1% versus DIA (Dow) +9.9%, SPY (S&P 500) +15.0%, QQQ (Nasdaq 100) +23.7% and IWM (Russell 2000) +15.4%.

Volume & Liquidity 1.15× 3-mo avg
Today 1,743,035 3-mo avg 1.5M
1W
1.7M
1M
1.6M
3M
1.5M
6M
2.0M
YTD
2.0M
1Y
2.0M

TVTX most recently traded 1,743,035 shares against a 3-month average daily volume of 1.5M.

More News

Read More
News headline image
Travere Therapeutics Announces Planned Chief Executive Officer Transition
September 21, 2026
From Travere Therapeutics, Inc.
Via Business Wire
Travere Therapeutics (NASDAQ:TVTX) Passes Minervini Trend Template With High-Growth Momentum ↗
September 21, 2026
Via Chartmill
Travere Therapeutics (NASDAQ:TVTX) Beats Q2 Revenue Estimates on FILSPARI Sales Growth ↗
August 04, 2026
Via Chartmill
Travere Therapeutics (NASDAQ:TVTX) Earns Perfect Ratings in Breakout Setup Screen ↗
July 28, 2026
Via Chartmill
Travere Therapeutics (NASDAQ:TVTX): High Growth Momentum Stock with Breakout Setup ↗
July 25, 2026
Via Chartmill
Travere Therapeutics (NASDAQ:TVTX) - High Growth Momentum and Technical Breakout Setup ↗
July 02, 2026
Via Chartmill
News headline image
Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum
September 17, 2026
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 11, 2026
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Sees FILSPARI FSGS Launch Top Expectations, Expands Renal Pipeline ↗
August 18, 2026
Via MarketBeat
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 12, 2026
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics (TVTX) Q2 2026 Earnings Call Transcript ↗
August 11, 2026
Via The Motley Fool
Topics Earnings
News headline image
Travere Therapeutics to Participate at Upcoming Investor Conferences
August 05, 2026
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Q2 Earnings Call Highlights ↗
August 04, 2026
Via MarketBeat
Topics Earnings
News headline image
Travere Therapeutics Reports Second Quarter 2026 Financial Results
August 04, 2026
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics to Report Second Quarter 2026 Financial Results
July 28, 2026
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 10, 2026
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now ↗
June 19, 2026
Via InvestorPlace
News headline image
Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027
June 16, 2026
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 11, 2026
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress
June 04, 2026
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases
June 02, 2026
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy
May 27, 2026
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 12, 2026
From Travere Therapeutics, Inc.
Via Business Wire

Frequently Asked Questions

Is Travere Therapeutics, Inc. - Common Stock publicly traded?
Yes, Travere Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Travere Therapeutics, Inc. - Common Stock trade on?
Travere Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Travere Therapeutics, Inc. - Common Stock?
The ticker symbol for Travere Therapeutics, Inc. - Common Stock is TVTX on the Nasdaq Stock Market
What is the current price of Travere Therapeutics, Inc. - Common Stock?
The current price of Travere Therapeutics, Inc. - Common Stock is 56.93
When was Travere Therapeutics, Inc. - Common Stock last traded?
The last trade of Travere Therapeutics, Inc. - Common Stock was at 10/02/26 04:00 PM ET
What is the market capitalization of Travere Therapeutics, Inc. - Common Stock?
The market capitalization of Travere Therapeutics, Inc. - Common Stock is 3.46B
How many shares of Travere Therapeutics, Inc. - Common Stock are outstanding?
Travere Therapeutics, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap